Geron Corporation (NASDAQ: GERN)
Geron Corporation is having an incredibly strong start to the trading session this morning, and for good reason. The company provided an update with regard to key clinical trials. As a result, investor excitement ensued, leading to gains and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:32), GERN is trading at $2.54 per share after a gain of $0.39 per share (17.92%) thus far today.
GERN Gains On Data Review Completion
As mentioned above, Geron Corporation is having a strong day in the market today after providing a clinical update. The company has announced the completion of its second internal data review for Imetelstat Trials. According to the announcement, Janssen Research & Development has completed its second internal data review for both IMerge and IMbark. Both are clinical trials of the telomerase inhibitor imetelstat in lower risk myelodyspalastic syndromes as well as relapsed or refractory myelofibrosis.
- IMbark – Current results suggest clinical benefit and a potential overall survival benefit associated with imetelstat treatment. As a result, the trial will continue unchanged to evaluate maturing efficacy and safety data, including an assessment of overall survival.
- IMerge – According to the PR released by GERN, the benefit/risk profile of imetelstat in the treated patients supports continued development in lower risk myelodysplastic syndromes.
Stop Wasting Your Time!!! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be watching GERN incredibly closely. In particular, we plan on following continued development surrounding imetelstat treatment, as the treatment seems to be overwhelmingly promising. We’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Wikimedia]